Chronic Kidney Disease, Type 1 Diabetes research hub

ASPIRE-1; Individual and combined endothelin receptor and SGLT2 antagonism in adults with type 1 diabetes mellitus and chronic kidney disease: a Phase 2, multicenter, open-label randomized cross-over trial

The ASPIRE-1 clinical trial is looking at new ways to protect the kidneys in adults with type 1 diabetes and chronic kidney disease. Researchers want to see if combining two different medicines works better to reduce kidney strain and protein leaks than taking just one medicine on its own.